Technology Bundle ID: TAB-2665

Peptide Vaccines Against Group A Streptococci

Request More Info
Licensing Contact:
Primary Inventors: 
Bernard Beall (CDC)
Co-Inventors: 
Edwin Ades (CDC), George Carlone (CDC), Jacquelyn Sampson (CDC)
Therapeutic Area: 
Infectious Disease
Development Status: 
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
Institute or Center: 
CDC

This invention relates to synthetic immunoreactive peptides, which are portions of the M proteins of the most prevalent Group A Streptococcus (GAS) serotypes in the United States. These peptides may be useful in development of a flexible, multivalent GAS vaccine. They can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies. Additionally, the peptides or isolated antibodies raised in response to the peptides may be useful for GAS diagnostics.

Applications:
  • Group A streptococci (GAS) vaccine
  • GAS therapeutics and diagnostics
  • Lab tools for exploring GAS
Advantages:
  • Easily adaptable to kit form
  • Multivalent vaccine that can be tailored for protection against specific GAS serotypes affecting a particular population

Patents

PCT Application PCT/US2002/015909
Filed on 2002-05-20
US Application 12/973,247
Filed on 2010-12-20
US Application 60/291,835
Filed on 2001-05-18
US Pat 7,407,664

Issued 2008-08-05
US Pat 7,883,710

Issued 2011-02-08
US Pat 8,420,107

Issued 2013-04-16
US Pat 8,637,050

Issued 2014-01-28

Various international patent applications pending or issued

Publications

Bruner M, et al.
PMID 12798606

Updated

Oct 23, 2013

Data Source: 
tts